Inhibition of influenza virus replication by constrained peptides targeting nucleoprotein

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 3, 2012, Pages 119-130

  Jiang, Hongbing ^a   Xu, Yidong ^a   Li, Li ^a   Weng, Leiyun ^a   Wang, Qiang ^a   Zhang, Shijian ^b,c   Jia, Baosen ^a   Hu, Hongxing ^a   He, Ying ^a   Jacob, Yves ^d   Toyoda, Tetsuya ^a,e,f  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b FUDAN UNIVERSITY   (China)

^c Roche R and D Center China Ltd   (China)

^d INSTITUT PASTEUR   (France)

^e Fukushimura Hospital   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CONOTOXIN; CYSTEINE; INFLUENZA VACCINE; NUCLEOPROTEIN; PROLINE; PROTEIN INHIBITOR; RNA POLYMERASE; TRANSACTIVATOR PROTEIN; ANTIVIRUS AGENT; CORE PROTEIN; NP PROTEIN, INFLUENZA A VIRUS; PEPTIDE; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; SILKWORM; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CELL STRAIN HEK293; CERCOPITHECUS; DOG; DRUG ANTAGONISM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; INFLUENZA VIRUS A H1N1; METABOLISM; PEPTIDE LIBRARY; VERO CELL;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DOGS; FEMALE; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; PEPTIDE LIBRARY; PEPTIDES; RNA-BINDING PROTEINS; VERO CELLS; VIRAL CORE PROTEINS; VIRUS REPLICATION;

EID: 84861547633     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1902     Document Type: Article

References (48)

1. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307.
2. Pang W, Tam SC, Zheng YT. Current peptide HIV type-1 fusion inhibitors. Antivir Chem Chemother 2009; 20:1-18.
3. Castel G, Chteoui M, Caignard G, et al. Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity. J Virol 2009; 83:10808-10820.
4. Real E, Rain JC, Battaglia V, et al. Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides. J Virol 2004; 78:7410-7417.
5. Olivera BM, Hillyard DR, Marsh M, Yoshikami D. Combinatorial peptide libraries in drug design: lessons from venomous cone snails. Trends Biotechnol 1995; 13:422-426.
6. Hara S, Yamakawa M. A novel antibacterial peptide family isolated from the silkworm, Bombyx mori. Biochem J 1995; 310:651-656.
7. Webster RG, Sharp GB, Claas EC. Interspecies transmission of influenza viruses. Am J Respir Crit Care Med 1995; 152:S25-S30.
8. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 2010; 28:4895-4902.
9. Plotkin JB, Dushoff J, Levin SA. Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proc Natl Acad Sci U S A 2002; 99:6263-6268.
10. Moss RB, Davey RT, Steigbigel RT, Fang F. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. J Antimicrob Chemother 2010; 65:1086-1093.
11. Kao RY, Yang D, Lau LS, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010; 28:600-605.
12. Su CY, Cheng TJ, Lin MI, et al. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci U S A 2010; 107:19151-19156.
13. Hurt AC, Ho HT, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther 2006; 4:795-805.
14. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48 Suppl 1:S3-S13.
15. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21:626-638.
16. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008; 78:91-102.
17. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-257.
18. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009; 15:155-162.
19. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953-956.
20. Duan S, Boltz DA, Seiler P, et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010; 6:e1001022.
21. Kiso M, Shinya K, Shimojima M, et al. Characterization of oseltamivir-resistant 2009 H1N1 pandemic infuenza A viruses. PLoS Pathog 2010; 6:e1001079.
22. Ohtsu Y, Honda Y, Sakata Y, Kato H, Toyoda T. Fine mapping of the subunit binding sites of influenza virus RNA polymerase. Microbiol Immunol 2002; 46:167-175.
23. Toyoda T, Adyshev DM, Kobayashi M, Iwata A, Ishihama A. Molecular assembly of the infuenza virus RNA polymerase: determination of the subunit-subunit contact sites. J Gen Virol 1996; 77:2149-2157.
24. Weng L, Du J, Zhou J, et al. Modification of hepatitis C virus 1b RNA polymerase to make a highly active JFH1-type polymerase by mutation of the thumb domain. Arch Virol 2009; 154:765-773.
25. Toyoda T, Hara K, Imamura Y. Ser624 of the PA subunit of influenza A virus is not essential for viral growth in cells and mice, but required for the maximal viral growth. Arch Virol 2003; 148:1687-1696.
26. Herlocher ML, Bucher D, Webster RG. Host range determination and functional mapping of the nucleoprotein and matrix genes of influenza viruses using monoclonal antibodies. Virus Res 1992; 22:281-293.
27. Neumann G, Watanabe T, Ito H, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 1999; 96:9345-9350.
28. Noguchi H, Matsumoto S. Protein transduction technology: a novel therapeutic perspective. Acta Med Okayama 2006; 60:1-11.
29. Jiang H, Zhang S, Wang Q, et al. Influenza virus genome C4 promoter/ origin attenuates its transcription and replication activity by the low polymerase recognition activity. Virology 2010; 408:190-196.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
31. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285:1569-1572.
32. Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In Knipe DM, Howley PM (Editors). Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins 2007; pp. 1647-1689.
33. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46:977-981.
34. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-986.
35. Hatada E, Hasegawa M, Mukaigawa J, Shimizu K, Fukuda R. Control of influenza virus gene expression: quantitative analysis of each viral RNA species in infected cells. J Biochem 1989; 105:537-546.
36. Li Z, Watanabe T, Hatta M, et al. Mutational analysis of conserved amino acids in the influenza A virus nucleoprotein. J Virol 2009; 83:4153-4162.
37. Tomai E, Butz K, Lohrey C, et al. Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes. J Biol Chem 2006; 281:21345-21352.
38. Luo G, Torri A, Harte WE, et al. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol 1997; 71:4062-4070.
39. Luo G, Colonno R, Krystal M. Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Virology 1996; 226:66-76.
40. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 2006; 80:11960-11967.
41. Ghanem A, Mayer D, Chase G, et al. Peptide-mediated interference with influenza A virus polymerase. J Virol 2007; 81:7801-7804.
42. Wunderlich K, Juozapaitis M, Ranadheera C, et al. Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase. Antimicrob Agents Chemother 2011; 55:696-702.
43. Wunderlich K, Mayer D, Ranadheera C, et al. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS ONE 2009; 4:e7517.
44. Elster C, Fourest E, Baudin F, et al. A small percentage of influenza virus M1 protein contains zinc but zinc does not influence in vitro M1-RNA interaction. J Gen Virol 1994; 75:37-42.
45. Wang Y, Xiao H, Wu N, et al. Characterization of the antiviral activity for influenza viruses M1 zinc finger peptides. Curr Microbiol 2011; 62:126-132.
46. Nasser EH, Judd AK, Sanchez A, Anastasiou D, Bucher DJ. Antiviral activity of influenza virus M1 zinc finger peptides. J Virol 1996; 70:8639-8644.
47. Palese P, Schulman JL. Inhibitors of viral neuraminidase as potential antiviral drugs. In Oxford JS (Editor). Chemoprophylaxis and virus infections of the upper respiratory tract. Cleveland: CRC Press 1977; pp. 189-205.
48. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.